Released July 22, 2021 | SUGAR LAND
en
Researched by Industrial Info Resources (Sugar Land, Texas)--The effects of COVID-19 on the global Pharmaceutical-Biotech Industry have been dramatic and seem here to stay (or at least for an extended period of time). Industrial Info's second day of its Mid-Year 2021 North American Market Outlook kicked off with an overview of North American spending, followed by more detailed dives into various industries. Among the presenters was Annette Kreuger, Industrial Info's vice president of research for the Pharma-Biotech Industry.
Kreuger pointed out that Industrial Info is tracking more than $11 billion in active COVID-related projects, more than half of which have a kickoff date in the future. In addition, COVID-19 has had a knock-on effect for demand for medications for other medical conditions; at the height of the pandemic, people were hesitant to seek medical treatment, causing these conditions to get worse over time.
Industrial Info is tracking more than 650 Pharma-Biotech projects, valued at $47.9 billion, that are under construction in North America, with a great deal of activity occurring in the U.S. Northeast, New England and Mid-Atlantic market regions, although activity is occurring everywhere. Among the trends being seen is the rise in projects by contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs), which serve other companies across the drug chain--from development through manufacturing. While these projects were going strong before COVID-19 hit, the pandemic has heightened them. Industrial Info is tracking about $24 billion in CMO and CDMO projects, which can range from small-run personalized medicines to large-scale vaccine production.
Kreuger also touched on the change in manufacturing processes, such as the implementation of artificial intelligence, digitization and automation in new "smart factories." Coupled with this is a rise in single-use systems and modular processing units to help minimize human contact and error in the manufacturing process. Kreuger asked, "Will there be a time when all plants don't have any workers except a few machine operators or technical people pushing the buttons? No, it's doubtful, but we're seeing a large increase in this, and that's expected to grow."
Another trend being seen in pharmaceutical-biotech plants is toward a continuous manufacturing process versus batch manufacturing. However, changing a manufacturing process in the U.S. is difficult, as when a new drug is authorized by the U.S. Food & Drug Administration, part of that approval is for the manufacturing process, and changing this requires new authorization. Kreuger cited examples of experiments done with continuous manufacturing where much more product was produced when compared with a batch process. In addition, continuous manufacturing can lead to smaller plant size and less energy used.
Industrial Info will wrap up its Mid-Year Market Outlook Update on Thursday, July 22, with a look at the Chemical Processing, Metals & Minerals and Power industries. Click here for more information and to register.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.
Kreuger pointed out that Industrial Info is tracking more than $11 billion in active COVID-related projects, more than half of which have a kickoff date in the future. In addition, COVID-19 has had a knock-on effect for demand for medications for other medical conditions; at the height of the pandemic, people were hesitant to seek medical treatment, causing these conditions to get worse over time.
Industrial Info is tracking more than 650 Pharma-Biotech projects, valued at $47.9 billion, that are under construction in North America, with a great deal of activity occurring in the U.S. Northeast, New England and Mid-Atlantic market regions, although activity is occurring everywhere. Among the trends being seen is the rise in projects by contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs), which serve other companies across the drug chain--from development through manufacturing. While these projects were going strong before COVID-19 hit, the pandemic has heightened them. Industrial Info is tracking about $24 billion in CMO and CDMO projects, which can range from small-run personalized medicines to large-scale vaccine production.
Kreuger also touched on the change in manufacturing processes, such as the implementation of artificial intelligence, digitization and automation in new "smart factories." Coupled with this is a rise in single-use systems and modular processing units to help minimize human contact and error in the manufacturing process. Kreuger asked, "Will there be a time when all plants don't have any workers except a few machine operators or technical people pushing the buttons? No, it's doubtful, but we're seeing a large increase in this, and that's expected to grow."
Another trend being seen in pharmaceutical-biotech plants is toward a continuous manufacturing process versus batch manufacturing. However, changing a manufacturing process in the U.S. is difficult, as when a new drug is authorized by the U.S. Food & Drug Administration, part of that approval is for the manufacturing process, and changing this requires new authorization. Kreuger cited examples of experiments done with continuous manufacturing where much more product was produced when compared with a batch process. In addition, continuous manufacturing can lead to smaller plant size and less energy used.
Industrial Info will wrap up its Mid-Year Market Outlook Update on Thursday, July 22, with a look at the Chemical Processing, Metals & Minerals and Power industries. Click here for more information and to register.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.
